Troels Yndigegn
@YndigegnY
Followers
393
Following
1K
Statuses
592
Chief of Department of Cardiology, Interventional Cardiologist, Lund, SWEDEN, @RealSwedeheart and #Reduce_Swedeheart
Lund, Sverige
Joined June 2017
Recently published within the SWENTRY/@RealSwedeheart Framework: Outcomes of Patients Receiving a Second Rescue Valve During Transcatheter Aortic Valve Implantation.
1
3
15
RT @DFCapodanno: In a prespecified subanalysis of the LANDMARK trial, the authors report on the comparison between the three individual arm…
0
19
0
#PCRLV Devil’s in the details as @DFCapodanno pointed out, possible reason for the different outcome in EarlyTAVR and Evolved - how fast do you deliver TAVR? @AndreasRck2 @MGtberg @PCRonline
0
2
7
RT @mmamas1973: And the celebration phd dinner for @YndigegnY - colleagues came up with a song for him and sang it. I think the gist is tha…
0
2
0
An honor and a pleasure!!
Congratulations to @YndigegnY for a successful defence of his PhD today (1st author of REDUCE-AMI trial ) at the University of Lund (I was the external examiner) with supervisors @AlexSchiopu10 and @DavidErlinge This was a public examination with a strong defence. Thankfully Mrs Yndigegn is still inviting me to the evening dinner celebration in honour of her husband 😜 Thank you to David and Alex for hosting me in Lund with a memorable dinner last night
1
0
14
RT @JEscaned: 5 year outcomes of DEFINE FLAIR trial published in @JAMACardio (+ editorial). Below outcomes of patie…
0
17
0
RT @FrobertOle: Bears are amazing and offer valuable lessons for our lifestyle. My debut book is launching soon—grab your copy today! This…
0
4
0
@mmamas1973 @HanCardiomd @DrRyanPDaly @SJGreene_md @mvaduganathan @RyanTedfordMD @AnastasiaSMihai @DrMarthaGulati @VietHeartPA @pabeda1 @BartoszHudzik It’s an excellent Metaanalysis and the authors have a very thorough discussion on the modifiers of Bblcks mortality benefits in the reperfusion era. I was happy to review this (in another journal) and recommended accept however editorial decision was not in favor.
0
1
3
@FrobertOle @gabrielsteg A well deserved recognition of your immense efforts @FrobertOle @MGtberg @DavidErlinge
0
0
5
@drandrewsharp Did it happen upfront or when advancing valve? In these TF cases I tend to choose another delivery sheath (platform) than the one shown if the case allows.
1
0
1
@h_evald @FrobertOle As you know they had to undergo early invasive strategy and in this patient group routine is revasc. PCI for most and CABG some. We have planned upcoming sub-studies also on vessel analysis, so will have to get back to you with a definitive answer.
0
0
2
RT @h_evald: @FrobertOle @YndigegnY Congratulations. How many patients were left with incomplete revascularization? Some were in FULL REVAS…
0
1
0
@h_evald @FrobertOle Excellent question! All patients underwent invasive strategy and I was never contacted from local PIs on CTOs - my guess is close to 0.00% as these are low-risk MIs with mainly 1-2 VD. I know 1 patient in Sweden had a stenosis in a septal branch which was not revascularized.
1
0
2
RT @BartoszHudzik: Long-term beta-blocker use in pts w/ #AMI & preserved #EF didn’t reduce risk of #death or new #MI compared to no BB use…
0
5
0
@dranulala @athenapoppas @JJheart_doc @MinnowWalsh @manesh_patelMD @DLBHATTMD @SripalBangalore @ShashankSinhaMD @DrMarthaGulati @ShelleyZieroth @ShelleyWood2 @vbluml @QuentinYoumans @NMHheartdoc Great session, thank you @dranulala @athenapoppas! Those who watched the eclipse instead missed the enlightenment ☺️ Comment on Bblcks in midrange LVEF (“50 is the new 40?”) can be read here: and the study by Soo et al.: 10.1093/ehjcvp/pvaa029.
0
0
2
RT @DrDeepMD: I’ve had more than a handful of cardiologists get all up in my grill about the importance of having patient on beta blockers…
0
4
0
@kaulcsmc @drandrewsharp @vineetcardio @FrobertOle @drjohnm We published our reasons for re-evaluating generic pharmacotherapies in an RRCT a couple of years ago.
0
0
1
RT @drandrewsharp: @kaulcsmc @vineetcardio @FrobertOle @YndigegnY @drjohnm What would be mechanism of B-blocker benefit? They aim to: 1.Red…
0
2
0
@kaulcsmc @FrobertOle @drjohnm The REDUCE-AMI trial is the only trial powered to guide decision in post MI-patients with LV =/>50%. The KM-curves are virtually overlapping and if cross-over was supposed to affect the result one would expect an early delta which would disappear and this is not the case.
0
1
8
@EdwardP60483089 @drjohnm We have a meta-analysis by @SripalBangalore numerous observational studies and now a trial w >5000 pts to guide therapy in these pts. What evidence does those still advocating giving “target-dose” (200mg metoprolol) to a fully revascularized MI-pt with normal LV have?
1
0
1